Centroflora CMS, a Luxembourg-based venture between Swiss company CMS Pharma and Centroflora Group of Brazil, is changing its name to C2 Pharma.
The new name was chosen to symbolise the close relationship between the two partners and reflects the company’s focus on the pharmaceutical business.
Andrew Bardot, CEO at C2 Pharma, said: “Our new identity is streamlined and focused, while incorporating the heritage the company has built up since it was established in 2014. We look forward to introducing the new brand to our existing customers and suppliers as well as to new contacts at CPhI 2017 in Frankfurt from 24-26 October on stand 11.0. B40.”
The anticipated formal registration of the company’s name (C-squared Pharma S.à r.l) with the Luxembourg authorities is expected to be concluded in December 2017, followed by the regulatory update to the CEP and US-DMF filings for Atropine Sulfate and Homatropine Methylbromide at the relevant authorities.
